These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. Mozaffari S; Salehi D; Mahdipoor P; Beuttler R; Tiwari R; Aliabadi HM; Parang K Eur J Med Chem; 2021 Dec; 226():113836. PubMed ID: 34537446 [TBL] [Abstract][Full Text] [Related]
4. Comparative Molecular Transporter Properties of Cyclic Peptides Containing Tryptophan and Arginine Residues Formed through Disulfide Cyclization. Mohammed EHM; Mandal D; Mozaffari S; Abdel-Hamied Zahran M; Mostafa Osman A; Kumar Tiwari R; Parang K Molecules; 2020 Jun; 25(11):. PubMed ID: 32498339 [TBL] [Abstract][Full Text] [Related]
5. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Nasrolahi Shirazi A; Tiwari R; Chhikara BS; Mandal D; Parang K Mol Pharm; 2013 Feb; 10(2):488-99. PubMed ID: 23301519 [TBL] [Abstract][Full Text] [Related]
6. Novel cleavable cell-penetrating peptide-drug conjugates: synthesis and characterization. Lelle M; Frick SU; Steinbrink K; Peneva K J Pept Sci; 2014 May; 20(5):323-33. PubMed ID: 24677287 [TBL] [Abstract][Full Text] [Related]
7. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells. Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477 [TBL] [Abstract][Full Text] [Related]
8. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy. Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710 [TBL] [Abstract][Full Text] [Related]
9. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer. Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate. Chhikara BS; Mandal D; Parang K J Med Chem; 2012 Feb; 55(4):1500-10. PubMed ID: 22276998 [TBL] [Abstract][Full Text] [Related]
12. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells. Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine as Molecular Transporters. El-Sayed NS; Miyake T; Shirazi AN; Park SE; Clark J; Buchholz S; Parang K; Tiwari R Molecules; 2018 Jun; 23(7):. PubMed ID: 29966296 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates. Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919 [TBL] [Abstract][Full Text] [Related]
15. Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death. Movafegh B; Jalal R; Mohammadi Z; Aldaghi SA Anticancer Agents Med Chem; 2018; 18(10):1448-1456. PubMed ID: 29651964 [TBL] [Abstract][Full Text] [Related]
16. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers. Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580 [TBL] [Abstract][Full Text] [Related]
17. New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity. Yu J; Mao X; Yang X; Zhao G; Li S Molecules; 2024 Apr; 29(8):. PubMed ID: 38675578 [TBL] [Abstract][Full Text] [Related]
18. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer. Park SE; Shamloo K; Kristedja TA; Darwish S; Bisoffi M; Parang K; Tiwari RK Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277465 [TBL] [Abstract][Full Text] [Related]
19. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy. Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168 [TBL] [Abstract][Full Text] [Related]
20. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]